TOKYO – Japan's Ono Pharmaceutical Co. Ltd. recently got into a public debate at home about the price of its cancer drug, Opdivo (nivolumab), which critics argue could bring too great a burden on the national welfare system.
TOKYO – Japan's Ono Pharmaceutical Co. Ltd. recently got into a public debate at home about the price of its cancer drug, Opdivo (nivolumab), which critics argue could bring too great a burden on the national welfare system. The company, however, said an analyst's estimates as to the amount of people that will use the anti-PD-1 drug and the length of time for which they will use it are both exaggerated.
TOKYO – Biopharmaceutical companies look to benefit, at least in the short term, after Japan's Prime Minister Shinzo Abe put off a planned 2 percent consumption tax hike scheduled for 2017. The increase now will not be introduced until at least October 2019.
TOKYO – Biopharmaceutical companies look to benefit, at least in the short term, after Japan's Prime Minister Shinzo Abe put off a planned 2 percent consumption tax hike scheduled for 2017. The increase now will not be introduced until at least October 2019.
TOKYO – Earnings at major Japanese pharmaceutical companies announced for the first quarter of this year or for the entire fiscal 2015 were mixed at best.
TOKYO – Earnings at major Japanese pharmaceutical companies announced for the first quarter of this year or for the entire fiscal 2015 were mixed at best.
